Drug-eluting balloon: New tool in the box

Expert Review of Medical Devices

Volumn 7, Issue 3, 2010, Pages 381-388

  Sharma, Sumeet ^a   Kukreja, Neville ^a   Christopoulos, Christos ^a   Gorog, Diana A ^a,b  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug eluting balloon; Drug eluting stent; In stent restenosis; Paclitaxel; Percutaneous coronary intervention

Indexed keywords

GENISTEIN; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ANTINEOPLASTIC ACTIVITY; BARE METAL STENT; DRUG CHOICE; DRUG EFFICACY; DRUG ELUTING BALLOON; DRUG ELUTING STENT; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; HUMAN; HYDROPHOBICITY; IN-STENT RESTENOSIS; LIPOPHILICITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; REVIEW; SINGLE DRUG DOSE; SUSTAINED RELEASE PREPARATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BALLOON DILATATION; CATHETERIZATION; CLINICAL TRIALS AS TOPIC; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS;

ANGINA;

EID: 77951864101     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.10.5     Document Type: Review

References (63)

1. King SB 3rd, Schlumpf M. Ten-year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experience. J. Am. Coll. Cardiol. 22 (2), 353-360 (1993). (Pubitemid 23214545)
2. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am. J. Cardiol. 84, 462-466 (1999). (Pubitemid 29398670)
3. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 316 (12), 701-706 (1987). (Pubitemid 17036474)
4. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N. Engl. J. Med. 354 (5), 483-495 (2006).
5. Lüscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis. Circulation 115, 1051-1058 (2007).
6. Mach F. Toward new therapeutic strategies against neointimal formation in restenosis. Atheroscler. Thromb. Vasc. Biol. 20, 1699-1700 (2000). (Pubitemid 30470581)
7. Mudra H, Regar E, Klauss V et al. Serial follow-up after optimized ultrasound guided deployment of Palmaz-Schatz stents. Circulation 95, 363-370 (1997).
8. Hoffman R, Mintz GS, Dussaillant RG et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 94, 1247-1254 (1996). (Pubitemid 26307249)
9. Kearney M, Pieczek A, Haley L et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 95, 1998-1200 (1997). (Pubitemid 27184264)
10. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller K-M. Acute and chronic tissue response to coronary stent implantation: pathologic fndings in human specimen. J. Am. Coll. Cardiol. 35, 157-163 (1999). (Pubitemid 30061274)
11. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 331 (8), 489-495 (1994). (Pubitemid 24256751)
12. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronarystent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331 (8), 496-501 (1994). (Pubitemid 24256752)
13. Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N. Engl. J. Med. 324 (1), 13-17 (1991).
14. Holmes DR Jr, Savage M, LaBlanche JM et al. Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 106 (10), 1243-1250 (2002). (Pubitemid 34988643)
15. Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N. Engl. J. Med. 344, 250-256 (2001).
16. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary b radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 359, 551-557 (2002). (Pubitemid 34178435)
17. Costa MA, Sabate M, van der Giessen WJ et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 100, 789-792 (1999). (Pubitemid 29398874)
18. Serruys PW, van Hout B, Bonnier H et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352 (9129), 673-681 (1998). (Pubitemid 28398701)
19. Gupta V, Aravamuthan BR, Baskerville S et al. Reduction of subacute stent thrombosis (SAT) using heparin-coated stents in a large-scale, real world registry. J. Invasive Cardiol. 16 (6), 304-310 (2004). (Pubitemid 38715811)
20. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349 (14), 1315-1323 (2003). (Pubitemid 37186209)
21. Stone G, Ellis S, O'Shaughnessy CD et al. Prospective, randomized evaluation of paclitaxel-eluting stents compared to vascular brachytherapy for treatment of in-stent restenosis: the TAXUS-V ISR trial. JAMA 295, 1253-1263 (2006).
22. Holmes DR, Teirstein PS, Satler LF et al. The SISR trial: a randomized trial comparing the sirolimus eluting stent with vascular brachytherapy for the treatment of in-stent restenosis from bare met al. stents. JAMA 295, 1264-1273 (2006).
23. Mukherjee D, Moliterno DJ. Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. JAMA 295, 1307-1309 (2006).
24. Maisel WH. Unanswered questions - drug-eluting stents and the risk of late thrombosis. N. Engl. J. Med. 356 (10), 981-984 (2007). (Pubitemid 46376797)
25. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (9562), 667-678 (2007). (Pubitemid 46281313)
26. Hwang CW, Wu D, Edelman ER. Physiological transport forces governing drug distribution for stent-based delivery. Circulation 104, 600-605 (2001). (Pubitemid 32738132)
27. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96, 636-645 (1997). (Pubitemid 27329445)
28. Iofna E, Langenberg R, Blindt R et al. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxeleluting stents in the treatment of de novo coronary lesions. Am. J. Cardiol. 98, 1022-1027 (2006). (Pubitemid 44486136)
29. Van der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked infammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94, 1690-1697 (1996).
30. Lemos PA, Hoye A, Goedhart D et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) study: Circulation 109, 1366-1370 (2004). (Pubitemid 38387822)
31. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy and future. Circulation 90, 2070-2082 (1994).
32. Goldman B, Blanke H, Wolinsky H. Infuence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase: a new catheter approach. Atherosclerosis 65, 215-225 (1987). (Pubitemid 17073849)
33. Camenzind E. Treatment of in-stent restenosis - back to the future? N. Engl. J. Med. 355 (20), 2149-2151 (2006). (Pubitemid 44749325)
34. Wilensky RL, March KL, Gradus-Pizlo I et al. Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am. Heart J. 129, 852-859 (1995).
35. Camenzind E, Bakker WH, Reijs A et al. Site-specifc intracoronary heparin delivery in humans after balloon angioplasty: a radioisotopic assessment of regional pharmacokinetics. Circulation 96, 154-165 (1997). (Pubitemid 27298417)
36. Herdeg C, Oberhoff M, Baumbach A et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and effcacy in vivo (Double Balloon). J. Am. Coll. Cardiol. 35, 1969-1976 (2000). (Pubitemid 30342882)
37. Oberhoff M, Kunert W, Herdeg C et al. Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porus balloon catheter. Basic Res. Cardiol. 96, 275-282 (2001). (Pubitemid 32433062)
38. Baumbach A, Herdeg C, Kluge M et al. Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Catheter. Cardiovasc. Interv. 47 (1), 102-106 (1999). (Pubitemid 29309572)
39. O'Keefe JHJ, McCallister BD, Bateman TM et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J. Am. Coll. Cardiol. 19, 1597-1600 (1997).
40. Muller DWM, Topol EJ, Abrams GD et al. Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J. Am. Coll. Cardiol. 20, 460-466 (1992).
41. Sheiban I, Anselmino M, Moretti C et al. Effect of a novel drug-eluted balloon coated with Genistein before stent implantation in porcine coronary arteries. Clin. Res. Cardiol. 97 (12), 891-898 (2008).
42. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N. Engl. J. Med. 332, 1004-1014 (1995).
43. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ. Res. 86, 879-884 (2000).
44. Sollot SJ, Cheng L, Pauly RR et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. 95, 1869-1876 (1995).
45. Scheller B, Speck U, Romeike B. Contrast media as carriers for local drug delivery successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur. Heart J. 24 (15), 1462-1467 (2003). (Pubitemid 36961837)
46. Scheller B, Speck R, Abramjuk I, Bernhardt R, Böhm M, Nickenig G. Pacliaxel balloon coating, a novel method for prevention and therapy of restenosis Circulation 110, 810-814 (2004). (Pubitemid 39096008)
47. Speck U, Scheller B, Abramjuk C. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries Radiology 240, 411-418 (2006). (Pubitemid 44098636)
48. Cremers B, Speck U, Kaufels N et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb. Haemost. 101 (1), 201-206 (2009).
49. Cremers B, Biedermann M, Mahnkopf D, Böhm M, Scheller B. Comparison of two different paclitaxelcoated balloon catheters in the porcine coronary restenosis model. sClin. Res. Cardiol. 98 (5), 325-330 (2009).
50. Scheller B, Hehrlein C, Bocksch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 355, 2113-2124 (2006). (Pubitemid 44749319)
51. Scheller B, Hehrlein C, Bocksch W. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter Clin. Res. Cardiol. 97 (10), 773-781 (2008).
52. Scheller B. PEPCAD I & II. Presented at: European Association of Percutaneous Cardiovascular Intervention. Barcelona, Spain, 13 May (2008).
53. Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119, 2986-2994 (2009).
54. Hamm CW. PEPCAD III. Presented at: American Heart Association. Orlando, FL, USA, 14 November (2009).
55. Fanggiday JC, Stella PR, Guyomi SH, Doevendans PA. Safety and effcacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions the DEBIUT (drug-eluting balloon in bifurcaton utrecht) registry Catheter. Cardiovasc. Interv. 71 (5), 629-635 (2008).
56. Cortese B. The Piccoleto Trial. Presented at: European Association of Percutaneous Cardiovascular Intervention 2009. Barcelona, Spain, 19-22 May (2009).
57. Tepe G, Zeller T, Albrecht T et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N. Engl. J. Med. 358, 689-699 (2008). (Pubitemid 351240748)
58. Werk M, Langner S, Reinkensmeier B et al. Inhibition of restenosis in femoropopliteal arteries paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 118, 1358-1365 (2008).
59. De Labriolle A, Pakala R, Bonello L, Lemesle G, Scheinowitz M, Waksman R. Paclitaxel-eluting balloon: from bench to bed. Catheter. Cardiovasc. Interv. 73, 643-653 (2009).
60. Waksman R, Pakala R. Drug-eluting balloon: the comeback kid? Circ. Cardiovasc. Interv. 2, 2352-2358 (2009).
61. Shah VM, Mintz GS, Apple S, Weissman NJ. Background incidence of late malapposition after bare met al. stent implantation. Circulation 106, 1753-1755 (2002).
62. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of late stent malapposition. Circulation 107, 2660-2663 (2003).
63. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 (6), 701-705 (2004). (Pubitemid 38222887)